Matinas BioPharma Provides Update On MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients With Complete Clinical Resolution
Portfolio Pulse from Benzinga Newsdesk
Matinas BioPharma announced updates on its MAT2203 Compassionate/Expanded Use Access Program, reporting complete clinical resolution in all 5 patients who completed treatment for serious fungal infections. The program has enrolled 19 patients with various invasive fungal infections. Additionally, patients who switched to MAT2203 from AmBisome due to renal toxicity experienced a reversal of renal impairment.
February 26, 2024 | 1:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Matinas BioPharma's MAT2203 shows significant promise in treating serious fungal infections, with a 100% clinical resolution rate in completed cases.
The positive outcomes from the MAT2203 program, including complete clinical resolution in treated patients and successful management of renal toxicity, could significantly enhance Matinas BioPharma's reputation and potentially increase demand for MAT2203. This, in turn, may positively impact the company's stock price in the short term as investors react to the promising results.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100